As of 06 Nov 2026 06:52 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2023/008 (03 Feb 2023): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Sulfasalazine (Salazopyrin®) 500mg suppositoriesaffected product · inferred from phrasing | Out of stock, as stated | w/c 20th March 2023precision: a month · window end 26 Mar 2023, derived from “w/c 20th March 2023” | notice of 03 Feb 2023 |
| Alternative aminosalicylic acid (5-ASA) containing suppositoriesclass-level statement by the source, not a named product · inferred from phrasing | Stated as available | — not stated for this line | notice of 03 Feb 2023 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register — 3 earlier protocols on this record have expired: SSP014 (to 01 Apr 2022), SSP018 (to 25 Mar 2022), SSP008 (to 08 Mar 2021). Matching is by name until identifier coding lands.
Named in the source as remaining available
The latest recorded notice names no alternative as remaining available.
Identifiers — Sulfasalazine
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name (presentation name), confidence 0.90 — grouping under review where marked Release Jul 2026.
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
Notified short 3 times on record since 2022. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 03 Feb 2023 | Medicine Supply Notification: Sulfasalazine (Salazopyrin®) 500mg suppositories | Supply notification | Tier 2 | MSN/2023/008 |
| 21 Dec 2022 | Medicine Supply Notification: Sulfasalazine 250mg in 5ml oral suspension sugar free | Supply notification | Tier 2 | MSN/2022/110 |
| 16 Mar 2022 | Medicine Supply Notification: Sulfasalazine (Salazopyrin® ) 500mg tablets | Supply notification | Tier 2 | MSN/2022/028 |
Also recorded under
Bracketed names seen in this medicine's notice titles: salazopyrin. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
NHS Scotland issues its own Medicine Supply Alert Notices. These match this medicine's name; they are shown beside, never added to, the England record.
- MSAN(2023)3 Sulfasalazine 250mg in 5ml oral suspension sugar free · issued 16 Jan 2023 · valid until until early June 2023, as stated · matched by name PDF ↗
- MSAN(2020)105 Salazopyrin En-Tabs® (sulfasalazine) 500mg tablets · issued 23 Oct 2020 · valid until early December 2020, as stated · matched by name PDF ↗
- MSAN(2020)79 Sulfasalazine 250mg/5mL oral suspension (Rosemont) · issued 11 Aug 2020 · valid until End September 2020 - update to MSAN (2020)31, as stated · matched by name PDF ↗
- MSAN(2020)50 Salazopyrin® (sulfasalazine) 500mg suppositories · issued 01 Jun 2020 · valid until w/c 15 June 2020, as stated · matched by name PDF ↗
- MSAN(2020)40 Salazopyrin® (sulfasalazine) 500mg suppositories · issued 14 May 2020 · valid until 5 June 2020, as stated · matched by name PDF ↗
- MSAN(2020)31 Sulfasalazine 250mg/5mL oral suspension (Rosemont) · issued 30 Apr 2020 · valid until End August 2020, as stated · matched by name PDF ↗